Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zynrelef vs Adductor Canal Block for Pain After TKA
NCT05751421Phase 3Unknown
- Sponsor
- Rothman Orthopaedics
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bupivacaine + meloxicam in postoperative pain, sponsored by Rothman Orthopaedics. Primary endpoints: Postoperative pain at 14 days and Opioid consumption at 14 days. Status: unknown.
02
Drugs
bupivacaine + meloxicam
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05751421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751421.